Paris, July 09, 2020 – Kanabiz has developed a cannabis-specificplatform, and offers a unique opportunity for the many producers and resellers of products at CBD to be able to offer their products to a much wider international audience, thanks to automatic legal filters according to the legal status of product components (CBD, THC, CBG…) developed by the Kanabiz website..
Cédric Billot, founder of Kanabiz, explains: “There are more and more manufacturers of products in CBD, and it has not been easy for them to make a place on the internet. Kanabiz intervenes in this direction and helps them to develop, bringing them international visibility through our legally specialized platform and our translations into several languages. »
Kanabiz is keen to offer its hand-picked solutions for their quality, composition and low ecological impact. Products containing CBD on the Kanabiz platform and sold in France comply with current legislation,with a THC content of no more than 0.2%.
“The legal framework for the cannabis industry is constantly evolving. Due to the growing popularity of CBD, more and more consumers want to try these new products, without always being aware of what is legal and what is not. As a result, we have developed Kanabiz, so that all consumers are legally safe and confident when they order, wherever they are. Explains Cédric Billot, founder of Kanabiz.
In order to continue to develop Kanabiz, the company has successfully completed its first fundraising with private investors,and will continue its expansion with the launch of the site in other markets (Spanish, Portuguese, Italian…) during the year 2020.
Kanabiz is a French platform offering a full range of products containing CBD (cannabidiol): oils, concentrates, vaping liquids, cosmetics, dietary supplements and beverages, but also a wide range of accessories.
Kanabiz is owned by C4B International, which specializes in marketing and legal monitoring of the cannabis industry, and was founded in 2019 by Cédric Billot, who has a keen knowledge of the cannabis market in France and Europe.
The platform has been available in Europe in English and French since the end of 2019.
Two unique new perfumes containing CBD oil are taking the world of fragrance by storm! Launched earlier this year by international luxury perfume house Fragrance Du Bois and with an olfactory signature that is unique to perfumery, these new creations are sexy, intoxicating and utterly addictive.
Fragrance Du Bois is a name synonymous with the creation of iconic luxury perfumes using the world’s most rare and expensive natural ingredients, including its signature Oud oils, Rose Absolute, Amber and Sandalwood. It seems unlikely that cannabis or marijuana extract should join this illustrious list of ingredients but through the work of the magical perfumers at Fragrance Du Bois, that is exactly what has happened, with amazing results! CBD oil is the oil extracted from legally grown cannabis plants that contain none of the psychoactive properties usually associated with cannabis and marijuana. In fact CBD oil and the myriad of products that now contain it are fast becoming the go to health and wellness supplements of choice for treating a whole range of conditions, with many medical experts now acknowledging its beneficial properties.
Shadi Samra, Head of Perfumery at Fragrance Du Bois, says: “Since our inception we have always sought out new and intriguing notes and on a personal level this is my passion! The starting point was the pure Oud oils and we were one of the first perfume houses to use real Oud oils in commercial perfumes instead of synthetic alternatives. We then moved through the whole spectrum of natural and rare ingredients. Cannabis has been a revelation and we first came across it through research we have been doing into Oud oils, which have similar health benefits to CBD oils. We intended to launch one perfume using Cannabis oils but when it came down to it, we couldn’t choose between the final two! So being an independent perfume house with nothing to hold us back, we launched both!”
He added: “As a fragrance note, Cannabis oil is vaguely floral, with a hint of green, herbaceous earthiness. In both versions, the Blue and the Intense, we added the exact pure Oud oil to balance the Cannabis green note adding richness to its smoky aromatic smell.”
Cannabis Blue is a lighter fresh summery fragrance while Cannabis Intense has a slightly heavier undertone. Each of these fragrances has been a great hit with perfume lovers and customers around the world, bringing a unique new edge to the world of modern perfumery. Fragrance Du Bois is redefining modern perfumery and with its #perfumeredefined, is creating some extraordinary new fragrances to delight perfumistas the world over!
Fragrance Du Bois Luxury Perfume Redefined is a unique sustainable story of vision, passion and creative integrity.
Brains Bioceutical Corp (“BRAINS” or the “Company”)(Vancouver, Canada), a global leader in pharmaceutical, wellness and veterinary cannabidiol (CBD) based Active Pharmaceutical Ingredient (API) production, is proud to announce its landmark accomplishment to bring Brazil’s first registered medical cannabis product under the new regulations that ANVISA put in place in December of 2019, Brains EU-GMP CBD API to the Brazilian market.
“Our partners in Brazil are a global leader in pharmaceutical production and clinical trials. I’m very proud of this historic moment, wherein we have combined our strengths to create the first registered product under the new regime. The standard we have set for the purity of our CBD is second to none. The team of world-renowned scientists and executives at Brains, continue to achieve landmark milestones with a relentless pursuit of historic firsts in the CBD industry. We look forward to monetizing and capitalizing on the resulting market opportunities that this launch will propel us towards. We now have registered CBD product in the epicenter of the European continent within the UK, and supply the CBD material to our South American partner for achieving the first registered cannabis product under the new ANVIA regulations in Brazil.” said Rick Brar, Chairman and CEO of Brains Bioceutical Corp.
Brains South American partner is a leader in the global pharmaceutical industry. Producing approximately 11.5 billion therapeutic doses per year, and has more than 4,200 employees. The company has one of the largest portfolios of generic drugs in Brazil, and supplies both South American and global markets. Since the recent announcement in December 2019, this is the first registered cannabis product under the special category created by ANVISA. We will be able to export Brains EU-GMP CBD API from the UK for our partner in Brazil to formulate their products to be sold in pharmacies and distributors in Brazil and potentially expand that to the rest of South America as the marketplace expands. All of our partners formulations adhere to the highest quality for manufacturing and testing with a view to making it the safest product available in the region. Under the terms of the agreement, Brains will provide its EU-GMP, CBD API to be used in the registered cannabis products.
“Now more than ever, it is important that patients have access to products that do not compromise on safety and quality. We believe that these products are bringing forward the highest quality product into South America. The Brains industry leading regulatory team was able to introduce the first cannabinoid based specials products in the UK and the first to supply our EU-GMP API ingredient to our partner in Brazil. Brains CBD is one of the few natural, plant-based API ingredients available anywhere on the planet. This team will successfully lead Brains to another first later this year, when we spearhead the reshaping of the CBD industry in the UK by taking the same approach for our Novel Foods application,” added Gurdeep Bains, President of Brains.
Since 2014, Brains subsidiary, BSPG Laboratories, has been a leader in clinical stage, natural source, cannabinoid manufacturing located in Sandwich, Kent, United Kingdom. Brains presently has Medicines and Healthcare Products Regulatory Agency’s (MHRA) approval to manufacture an approved pharmaceutical grade ingredient (API) for the global pharmaceutical industry. Having shipped over 100 kilos to Brazil over the past year, Brains has been providing patients in Brazil with reliable access for over 2 years.
About Brains Bioceutical Corp Brains Bioceutical Corp is a leader in GMP – certified production of naturally sourced active pharmaceutical ingredients (APIs) for the pharmaceutical and nutraceutical industries. Brains Bioceutical is one of the only natural plant-based cannabinoid active pharmaceutical ingredient (API) manufacturers in commercial production today and is involved in academic and clinical trials across the globe.
Brains Bioceutical Corp. Senior Management Team is made up of a rare hybrid of pharmaceutical and consumer goods executives-having held C-suite and other senior positions with companies such as GW Pharma, Merck, Seattle Seahawks, Golden State Warriors, Danone, Earthbound Farms, International Herbs, Cascadia Specialties and The Royal British Navy. This experience allows Brains to execute at a hyper-efficient level in the pharma and wellness categories.
Brains’ wholly owned subsidiary in the UK, BSPG Laboratories is one of only nine companies that has the commercial capability and EudraGMDP certification to produce CBD API, and is only one of four worldwide to source a natural plant based cannabidiol. Brains is currently manufacturing a line of phytocannabinoid THC-free CBD API products.
MHRA Registered API: Inspected and Registered with the MHRA (Medicines and Healthcare Products Regulatory Agency).
CAUTIONARY STATEMENT: This news release contains forward looking statements or forward-looking information (“forward-looking statements”) within the meaning of securities laws. Often, but not always, forward looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. All statements, other than statements of historical fact, in this news release are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance are not statements of historical fact and may be forward-looking statements. Risks, uncertainties and other factors involved with forward-looking statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements in this news release are reasonable, there can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
Following the successful inaugural two-day event in 2018, Medcann World Forum has officially announced the 2nd annual event in Malta set for November 19th – 21st.
Key speakers at this year’s summit will include, Malta’s Prime Minister, Dr. Joseph Muscat. In 2008 Dr. Muscat was elected as the leader of the Labour Party and was subsequently elected Prime Minister on the 11th of March 2013. Dr. Muscat won his second term as Prime Minister in June 2017.
Hendrik Knopp, the Managing Director of Aphria Germany will also be addressing the forum in 2019. Knopp has been at the helm of Aphria Germany since the company was set up and has recently lead the process which resulted in Aphria being successfully selected by the German Federal Institute for Drugs and Medical Devices to receive a license for the domestic cultivation of medical cannabis in Germany.
Tjalling Erkelens CEO at Bedrocan has also been announced as one of this year’s speakers. For the past 26 years, Erkelens has developed and standardized unique methods of producing cannabis to pharmaceutical standards, to a level achieved by no other company. His strong commitment to product quality resulted in the Dutch Bedrocan production facilities being approved for GMP/API (Good Manufacturing Practice/Active Pharmaceutical Ingredients) by the Dutch Health Authorities in 2017.
Additionally, Prof. Anthony Serracino will be speaking at this year’s event. Anthony Serracino Inglott is a Professor at the Department of Pharmacy, Faculty of Medicine and Surgery at the University of Malta. He is also the Chairman of the Malta Medicines Authority, Chairman of the Malta Laboratories Network and a member within the Ethics Committee, Faculty of Medicine and Surgery and the board of governors of the Malta Competition and Consumer Affairs Authority.
Medcann World Forum is set on bringing together policymakers, analysts, researchers and business leaders, that will provide key insights from the professionals at the forefront of the cannabis industry.
ABOUT MEDCANN WORLD FORUM
Medcann World Forum 2019 will take place at the Mediterranean Conference Centre which has long been considered one of Valletta’s most remarkable landmarks. Located towards the tip of Valletta peninsula, the MCC stands for distinction with magnificent views across the Grand Harbour. https://www.medcannworldforum.com/